CEO James Bonnar outlines how Nyrada (ASX: NYR) is developing new therapies for cardiovascular and neurological disorders, why the company is well positioned within the global markets and what gives them a competitive edge. James also talks about the recent achievements and plans to transition into clinical study phases, and answers listeners questions.

Nyrada Inc. is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological, and inflammatory diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need.

Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only.

Accurate time of recording, 24 June 2020 at 12pm AEST.